Vistagen Therapeutics, Inc. (VTGN)
Last updated: 2026-10-24 21:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Vistagen Therapeutics, Inc. (VTGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.18, with a market capitalization of $8.30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.18 to $5.14. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$8.30M | |
$0.19 | |
$140.70 | |
$0.18 | |
$0.19 | |
1.20M | |
12.53M | |
-- | |
$5.14 | |
$0.18 | |
-- | |
-- |
Vistagen Therapeutics, Inc. (VTGN) Latest Closing Stock Price
Vistagen Therapeutics, Inc. (VTGN) last closed at $0.19 as of 2026-10-23 23:19:00, unchanged from the previous close of $0.19.
During the latest regular trading session, VTGN traded between $0.18 and $140.70, with a volume of 1.20M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Vistagen Therapeutics, Inc. (VTGN) 7-Day Stock Price Change
Over the past seven days, Vistagen Therapeutics, Inc. (VTGN) moved from $0.21 to $0.18, representing a decline of 15.49% ($0.03).
The stock traded between $0.18 and $0.22 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 791.83 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
VTGN 52-Week Price Position
Position in Range: 0.1%
VTGN is currently trading at $0.18, placing it 0.1% of the way from its 52-week low of $0.18 to its 52-week high of $5.14. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Vistagen Therapeutics, Inc. (VTGN)?
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Vistagen Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 41 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Vistagen Therapeutics, Inc. (VTGN) Stock on MEXC
Eligible investors can buy real shares of Vistagen Therapeutics, Inc. (VTGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Vistagen Therapeutics, Inc. (VTGN) stock price today?
2.Is VTGN stock going up or down today?
3.What is VTGN pre-market price?
4.What is VTGN after-hours price?
5.Is VTGN stock trading now?
6.Where does VTGN sit relative to its 52-week high and low?
7.What sector is Vistagen Therapeutics, Inc. in?
8.What is Vistagen Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is VTGN valued in terms of P/E ratio and EPS?
10.Does Vistagen Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
VTGN Stock Calculator
Estimate the value between VTGN shares and USD.
VTGN Shares to USD
1.00 VTGN shares = 0.18 USD
Calculations are estimates based on the latest available price and are for reference only.


